MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
→
Sort
Language
Type
Field
Venue
Journal of Clinical Oncology
Topic
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

9,514 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
9,514 works in the cohort · of 4,299,418page 55 of 191

Labels cover 106 of 9,514 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 9,514 of 9,514 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

affgemma · no categorygpt · no categorymodels agree
Nivolumab plus ipilimumab (NIVO+IPI) vs gemcitabine-carboplatin (gem-carbo) chemotherapy for previously untreated unresectable or metastatic urothelial carcinoma (mUC): Final results for cisplatin-ineligible patients from the CheckMate 901 trial.
Michiel Simon Van Der Heijden, Matthew D. Galsky, Thomas Powles, Andrea Necchi, Dingwei Ye, Pengfei Zhang +13 more
2025· article· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
8
citations
affunlabeled
Oxaliplatin (OXP) plus protracted infusion 5-fluorouracil (PIFU) and external beam radiation (EBRT) prior to surgery (S) for potentially curable esophageal adenocarcinoma (EA): A Southwest Oncology Group (SWOG) phase II trial with molecular correlates (S0356)
Lawrence Leichman, Bryan Goldman, Jacqueline Benedetti, Kevin G. Billingsley, Charles R. Thomas, Syma Iqbal +4 more
2009· article· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
8
citations
affunlabeled
Phase I study of ECO-4601, a novel Ras pathway inhibitor
Petr Kavan, David Melnychuk, Adrian Langleben, Sharyn D. Baker, Ali Haider Bangash, C. Gauthier +5 more
2007· article· en· Journal of Clinical Oncology· Biochemistry, Genetics and Molecular Biology
machine prediction:candidate · noneconsensus · none
8
citations
affno abstractunlabeled
Dexamethasone for Cancer-Related Fatigue
Michael Franco, Leeroy William, Peter Poon, Arun Azad
2014· letter· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
8
citations
affgemma · no categorygpt · no categorymodels agree
A phase 3, two-stage, randomized study of mezigdomide, carfilzomib, and dexamethasone (MeziKd) versus carfilzomib and dexamethasone (Kd) in relapsed/refractory multiple myeloma (RRMM): SUCCESSOR-2.
Paul G. Richardson, Michael Amatangelo, James R. Berenson, Claudio Cerchione, Meletios Α. Dimopoulos, Charlotte Toftmann Hansen +13 more
2023· article· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
8
citations

How this was built: Screen · Findings · About